focus -WSS

focus

author：Wikipedia 2025-09-29 01:38:26 - browse：55677

Adam's take main illustration — Molly Ferguson/STAT

Behind the stellar commercial launch of Amylyx Pharmaceuticals’ treatment for ALS lies an uncomfortable question: Does early success of the drug, called Relyvrio, make it more complicated, perhaps impossible, to pull it from the market if we find out next year that it doesn’t work?

On Monday night, Amylyx said Relyvrio sales totaled $22 million in 2022 — a period that covers slightly more than one calendar quarter given the drug’s U.S. approval last September. The company said approximately 1,300 ALS patients were on Relyvrio at the end of December, and it expects that number to at least double by the end of the first quarter.

“We’re probably going to double, closer to triple, our revenue in Q1,” said James Frates, Amylyx’s chief financial officer, speaking on Monday night’s conference call.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Trump demands the U.S. pay no more for drugs than other countries … again
Next article： CRISPR pioneers react to Casgevy, first gene

WSS

Ransomware attacks on hospitals: Study outlines patient impact

Wegovy, Zepbound and weight loss drugs that preserve muscle

A rare thyroid diagnosis led to unexpected, all

FDA's Woodcock to retire early next year

Ransomware attacks on hospitals: Study outlines patient impact

How to protect patients from sexual assault

focus

focus

focus

Bright Health sells Medicare Advantage business to Molina

CRISPR pioneers react to Casgevy, first gene

Medical leaders decry Supreme Court decision on affirmative action

Poor hospice wound care hurts patients and families

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Readout Newsletter: Bayer's future, Merck Caraway acquisition, etc

FDA approval of Sarepta Duchenne genetic therapy gives me hope

CRISPR pioneers react to Casgevy, first gene

Cancer drug shortages should be causing more outrage

Weight loss drug costs may need more research, senator suggests

explore

In key trial, Verve's treatment lowers cholesterol levels in patients

What American doctors can learn from their Israeli counterparts

CRISPR pioneers react to Casgevy, first gene

The 10 drugs up first for Medicare price negotiation

Childhood cancer progress stalls for Black, Hispanic kids: Report

What American doctors can learn from their Israeli counterparts

hotspot

hotspot

knowledge

Wikipedia